Boston Scientific Co. (NYSE:BSX) Shares Acquired by Callan Capital LLC

Callan Capital LLC grew its position in Boston Scientific Co. (NYSE:BSX) by 16.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,233 shares of the medical equipment provider’s stock after purchasing an additional 592 shares during the quarter. Callan Capital LLC’s holdings in Boston Scientific were worth $378,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Turning Point Benefit Group Inc. acquired a new stake in shares of Boston Scientific in the 4th quarter valued at $309,000. Deseret Mutual Benefit Administrators raised its stake in Boston Scientific by 19.7% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 916 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 151 shares in the last quarter. Transcend Capital Advisors LLC raised its stake in Boston Scientific by 3.8% during the 4th quarter. Transcend Capital Advisors LLC now owns 7,434 shares of the medical equipment provider’s stock worth $664,000 after acquiring an additional 271 shares in the last quarter. Arcadia Investment Management Corp MI raised its stake in Boston Scientific by 36.7% during the 4th quarter. Arcadia Investment Management Corp MI now owns 856 shares of the medical equipment provider’s stock worth $76,000 after acquiring an additional 230 shares in the last quarter. Finally, Forte Capital LLC ADV raised its stake in Boston Scientific by 2.6% during the 4th quarter. Forte Capital LLC ADV now owns 6,266 shares of the medical equipment provider’s stock worth $560,000 after acquiring an additional 158 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 0.9 %

Shares of NYSE:BSX opened at $104.44 on Friday. The company has a market cap of $154.12 billion, a price-to-earnings ratio of 83.55, a PEG ratio of 2.79 and a beta of 0.80. The firm’s 50-day simple moving average is $97.98 and its 200-day simple moving average is $89.38. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a fifty-two week low of $65.52 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, equities research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. UBS Group lifted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Friday, January 10th. TD Cowen lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Finally, Truist Financial lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $107.39.

Insider Buying and Selling

In related news, CFO Daniel J. Brennan sold 67,333 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the sale, the chief financial officer now owns 225,808 shares of the company’s stock, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP John Bradley Sorenson sold 1,201 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 153,640 shares of company stock valued at $15,718,289. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.